Co-Authors
This is a "connection" page, showing publications co-authored by VIVEK SUBBIAH and MICHAEL TETZLAFF.
Connection Strength
0.233
-
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol. 2021 06; 32(6):817-819.
Score: 0.193
-
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct; 45(10):786-790.
Score: 0.040